API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 3 days · First seen · Last updated

Chilean approval of synthetic semaglutide

Overview

Chile’s Institute of Public Health (ISP) has granted sanitary registrations to Picmagluti, an injectable semaglutide solution developed by Dr. Reddy’s Laboratories Chile. This marks the first time a version of the active ingredient produced via chemical synthesis has been authorized in the country.

The ISP issued two specific registrations: one for 0.25 mg and 0.5 mg doses, and another for the 1 mg presentation. While the active ingredient is the same as the biological product Ozempic, the manufacturing processes differ, requiring distinct regulatory evaluations. The approved indication for Picmagluti is as a complementary treatment to diet and exercise for adults with type 2 diabetes with insufficient glycemic control.

Regulatory authorities have noted that the presence of the same active ingredient does not make these medications automatically interchangeable. The ISP is currently reviewing 11 additional applications for synthetic semaglutide from four different laboratories.

Entities

Chile · Picmagluti · Dr. Reddy’s Laboratories Chile · Public Health Institute of Chile · Institute of Public Health

Timeline

  1. [HEALTH] 2 sources
    Chile approves Picmagluti, first chemically synthesized semaglutide

    Chile's ISP has approved Picmagluti, a chemically synthesized semaglutide from Dr. Reddy’s Laboratories, providing a new alternative to biological versions like Ozempic.

  2. [HEALTH] 2 sources
    Chile approves Picmagluti as semaglutide alternative

    Chile's ISP has approved Picmagluti, a chemically synthesized semaglutide by Dr. Reddy’s Laboratories, as a new treatment option for adults with type 2 diabetes.

Sources

diarioestrategia.cl · elminuto.cl · envivo.rockandpop.cl · radiosanjoaquin.cl